- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00491140
Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab
September 30, 2008 updated by: Istituto Clinico Humanitas
Retrospective Study Assessing Molecular Features Predicting Response or Resistance to Cetuximab Therapy in Metastatic Colorectal Cancer Patients
The primary objective is to identify molecular features predicting response or resistance to cetuximab
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Secondary objective is to investigate association of genomic status of EGFR and HER-2 genes with clinical outcome, including objective response, time to progression and survival
Study Type
Observational
Enrollment (Actual)
85
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Milan
-
Rozzano, Milan, Italy, 20089
- Istituto Clinico Humanitas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Colorectal cancer patients treated with Cetuximab
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of colorectal cancer with available tumor tissue and clinical data; presence of at least one measurable lesion.
Exclusion Criteria:
- Less than 3 weeks after completion of previous radiotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Observation
Colorectal cancer patients
|
FISH and mutation analysis of multiple genes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Association of different biomarkers with Cetuximab sensitivity
Time Frame: Assessment every two months
|
Assessment every two months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Association of different biomarkers with time to progression and survival
Time Frame: At the end of the study
|
At the end of the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Armando Santoro, MD, Istituto Clinico Humanitas
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
May 1, 2007
Study Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
June 22, 2007
First Submitted That Met QC Criteria
June 22, 2007
First Posted (Estimate)
June 25, 2007
Study Record Updates
Last Update Posted (Estimate)
October 1, 2008
Last Update Submitted That Met QC Criteria
September 30, 2008
Last Verified
September 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICH n. 380
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.